A pilot study of mindful body awareness training as an adjunct to office-based medication treatment of opioid use disorder
Open accessAbstract
The purpose of this study was to pilot-test a mind-body intervention called Mindful Awareness in Body-oriented Therapy (MABT) as an adjunct to buprenorphine for individuals with opioid use disorder (OUD). MABT, a manualized 8 week protocol, teaches interoceptive awareness skills to promote self-care and emotion regulation. A small study was designed to assess MABT recruitment and retention feasibility, and intervention acceptability, among this population. Individuals were recruited from two office-based programs providing buprenorphine treatment within a large urban community medical center. Participants were randomized to receive either treatment as usual (TAU), or TAU plus MABT. Assessments administered at baseline and 10-week follow-up included validated self-report health questionnaires and a process measure, the Multidimensional Assessment of Interoceptive Awareness, to examine interoceptive awareness skills. An additional survey and exit interview for those in the MABT study arm were administered to assess intervention satisfaction. Results showed the ability to recruit and enroll 10 participants within two-weeks, and no loss to follow-up. The MABT study group showed an increase in interoceptive awareness skills from baseline to follow-up, whereas the control group did not. Responses to the satisfaction questionnaire and exit interview were positive, indicating skills learned, satisfaction with the interventionists, and overall perceived benefit of the intervention. In summary, study results demonstrated recruitment and retention feasibility, and high intervention acceptability. This pilot study suggests preliminary feasibility of successfully implementing a larger study of MABT as an adjunct to office-based medication treatment for opioid use disorder.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mindfulness has shown promise as an acceptable behavioral treatment for OUD comorbidities such as chronic pain and anxiety when used with buprenorphine/naloxone, even in primary care.
“Mindfulness has shown promise as an acceptable behavioral treatment for OUD comorbidities such as chronic pain and anxiety when employed in conjunction with buprenorphine/naloxone treatment, even within primary care 23,24.”
From Effects of a trauma-informed mindful recovery program on comorbid pain, anxiety, and substance use during primary care buprenorphine treatment: A proof-of-concept study (2023) · cites this paper as [24]
The Abstract and Results > Intervention Acceptability report that mindful body awareness training was acceptable as an adjunct to buprenorphine treatment for OUD; Method > Study Setting says one recruitment clinic was in primary care. Method > Measures includes anxiety and pain assessments, but the paper does not establish treatment benefit for chronic pain or anxiety, and it specifies buprenorphine rather than buprenorphine/naloxone. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredA few recent feasibility studies of mindfulness in office-based opioid treatment with buprenorphine/naloxone have been positive.
“A few positive feasibility studies have been published recently (Bloom-Foster & Mehl-Madrona, 2020; Price et al., 2020).”
From Feasibility and acceptability of mindful recovery opioid use care continuum (M-ROCC): A concurrent mixed methods study (2021) · cites this paper as Price et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910 · see citing works
A Global Measure of Perceived Stress
Cohen, S., Kamarck, T., & Mermelstein, R. (1983) · Journal of Health and Social Behavior · doi:10.2307/2136404 · Cited by 32,807 · see citing works
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765 · see citing works
Graneheim, U. H., & Lundman, B. (2004) · Nurse Education Today · doi:10.1016/j.nedt.2003.10.001 · Cited by 20,772 · see citing works
Diagnostic and Statistical Manual of Mental Disorders(DSM)
Leong, F. T. L. (2008) · Sage eBooks · doi:10.4135/9781412963978.n182 · Cited by 10,858 · see citing works
Gratz, K. L., & Roemer, L. (2004) · Journal of Psychopathology and Behavioral Assessment · doi:10.1023/b:joba.0000007455.08539.94 · Cited by 8,942 · see citing works
The PHQ-8 as a measure of current depression in the general population
Kroenke, K., Strine, T. W., Spitzer, R. L., Williams, J. B. W., Berry, J. T., & Mokdad, A. H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.026 · Cited by 5,121 · see citing works
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024 · see citing works
What's in a name? Qualitative description revisited
Sandelowski, M. (2010) · Research in Nursing & Health · doi:10.1002/nur.20362 · Cited by 4,975 · see citing works
Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century
Case, A., & Deaton, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518393112 · Cited by 2,759 · see citing works
Interoception: the sense of the physiological condition of the body
(Bud) Craig, A. (2003) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(03)00090-4 · Cited by 2,556 · see citing works
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312 · see citing works
The multidimensional assessment of interoceptive awareness (MAIA)
Mehling, W. E., Price, C., Daubenmier, J. J., Acree, M., Bartmess, E., & Stewart, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048230 · Cited by 1,429 · see citing works
Self-citationKeller, S., Bann, C. M., Dodd, S. L., Schein, J., Mendoza, T. R., & Cleeland, C. S. (2004) · The Clinical Journal of Pain · doi:10.1097/00002508-200409000-00005 · Cited by 1,233 · see citing works
Kaufman, E. A., Xia, M., Fosco, G., Yaptangco, M., Skidmore, C. R., & Crowell, S. E. (2016) · Journal of Psychopathology and Behavioral Assessment · doi:10.1007/s10862-015-9529-3 · Cited by 960 · see citing works
Psychometric properties of the Penn Alcohol Craving Scale
Flannery, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04349.x · Cited by 852 · see citing works
The neurocircuitry of impaired insight in drug addiction
Goldstein, R. Z., Craig, A. D. (., Bechara, A., Garavan, H., Childress, A. R., Paulus, M. P., & Volkow, N. D. (2009) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2009.06.004 · Cited by 641 · see citing works
The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making
Naqvi, N. H., & Bechara, A. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0268-7 · Cited by 598 · see citing works
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540 · see citing works
Diagnostic and Statistical Manual of Mental Disorders (DSM)
Matsuno, E. G. (2024) · The SAGE Encyclopedia of LGBTQ Studies · doi:10.4135/9781071891414.n132 · Cited by 527 · see citing works
Price, C. J., & Hooven, C. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.00798 · Cited by 519 · see citing works
Self-citationA neurocognitive approach to understanding the neurobiology of addiction
Noël, X., Brevers, D., & Bechara, A. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.01.018 · Cited by 436 · see citing works
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R., Kimber, J., Breen, C. L., & Davoli, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub2 · Cited by 358 · see citing works
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351 · see citing works
Interoception and drug addiction
Paulus, M. P., & Stewart, J. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.002 · Cited by 281 · see citing works
The role of interoception in addiction: A critical review
Verdejo‐García, A., Clark, L., & Dunn, B. D. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.05.007 · Cited by 270 · see citing works
Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.541 · Cited by 267 · see citing works
LaBelle, C. T., Han, S. C., Bergeron, A., & Samet, J. H. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.06.010 · Cited by 226 · see citing works
Long-term retention in Office Based Opioid Treatment with buprenorphine
Weinstein, Z., Kim, H. W., Cheng, D. M., Quinn, E. K., Hui, D. S. C., LaBelle, C. T., Drainoni, M., Bachman, S. S., & Samet, J. H. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.12.010 · Cited by 224 · see citing works
LESERMAN, J., LI, Z., DROSSMAN, D. A., & HU, Y. J. B. (1998) · Psychological Medicine · doi:10.1017/s0033291797006508 · Cited by 216 · see citing works
The role of interoception and alliesthesia in addiction
Paulus, M. P., Tapert, S. F., & Schulteis, G. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.08.005 · Cited by 168 · see citing works
A Randomized Trial of Cognitive Behavioral Therapy in Primary Care-based Buprenorphine
Fiellin, D. A., Barry, D. T., Sullivan, L. E., Cutter, C. J., Moore, B. A., O’Connor, P. G., & Schottenfeld, R. S. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.07.005 · Cited by 159 · see citing works
Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis
Yarborough, B. J. H., Stumbo, S. P., McCarty, D. W., Mertens, J. R., Weisner, C. M., & Green, C. A. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.12.031 · Cited by 158 · see citing works
Pierce, M., Bird, S. M., Hickman, M., Marsden, J., Dunn, G., Jones, A., & Millar, T. (2015) · Addiction · doi:10.1111/add.13193 · Cited by 155 · see citing works
Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year
Soeffing, J. M., Martin, L. D., Fingerhood, M., Jasinski, D. R., & Rastegar, D. A. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.05.003 · Cited by 144 · see citing works
Price, C. J., Thompson, E. A., Crowell, S., & Pike, K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.012 · Cited by 111 · see citing works
Self-citationPrice, C. J., Thompson, E. A., Crowell, S. E., Pike, K., Cheng, S. C., Parent, S., & Hooven, C. (2019) · Substance Abuse · doi:10.1080/08897077.2018.1488335 · Cited by 94 · see citing works
Self-citationPrice, C. J., Wells, E. A., Donovan, D. M., & Rue, T. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.09.016 · Cited by 90 · see citing works
Self-citationPatients' Reasons for Choosing Office-Based Buprenorphine: Preference for Patient-Centered Care
Korthuis, P. T., Gregg, J. L., Rogers, W. E., McCarty, D. W., Nicolaidis, C., & Boverman, J. F. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181cc9610 · Cited by 71 · see citing works
Public sector low threshold office-based buprenorphine treatment: outcomes at year 7
Bhatraju, E. P., Grossman, E., Tofighi, B., McNeely, J., DiRocco, D., Flannery, M., Garment, A. R., Goldfeld, K. S., Gourevitch, M. N., & Lee, J. D. (2017) · Addiction Science & Clinical Practice · doi:10.1186/s13722-017-0072-2 · Cited by 64 · see citing works
Donovan, D. M., Kadden, R. M., DiClemente, C. C., & Carroll, K. M. (2002) · American Journal on Addictions · doi:10.1080/10550490290088090 · Cited by 51 · see citing works
Interoceptive Awareness Is Important for Relapse Prevention
Price, C. J., & Smith-DiJulio, K. (2016) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000109 · Cited by 32 · see citing works
Self-citationPrice, C. J., Wells, E. A., Donovan, D. M., & Brooks, M. (2012) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2011.0126 · Cited by 28 · see citing works
Self-citationMultidimensional Assessment of Interoceptive Awareness - MAIAPreprint
Lazić, A., Lazarevic, L., Žeželj, I. L., et al. (2020) · OSF Preprints (OSF Preprints) · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Goldstein R, Craig AD, Bechara A, Garavan H, Childress AR, Paulus MP, & Volkow N (2010). The Neurocircuity of Impaired Insight. Trends in Cognitive Sciences, 13(9), 372– 378. PMC2844118 19716751
Cited by
Sorted by citations
Mindfulness and Behavior Change
Schuman-Olivier, Z., Trombka, M., Lovas, D. A., Brewer, J. A., Vago, D. R., Gawande, R., Dunne, J. P., Lazar, S. W., Loucks, E. B., & Fulwiler, C. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000277 · Cited by 435 · see citing works
Heim, N., Bobou, M., Tanzer, M., Jenkinson, P. M., Steinert, C., & Fotopoulou, A. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13576 · Cited by 61 · see citing works
Price, C. J., Sevinc, G., & Farb, N. A. S. (2023) · Brain Sciences · doi:10.3390/brainsci13101396 · Cited by 20 · see citing works
Self-citationSchuman‐Olivier, Z., Fatkin, T., Creedon, T. B., Samawi, F., Moore, S. K., Okst, K., Fredericksen, A. (., Oxnard, A. (., Roll, D., Smith, L., et al. (2023) · The American Journal on Addictions · doi:10.1111/ajad.13364 · Cited by 15 · see citing works
Fatkin, T., Moore, S. K., Okst, K., Creedon, T. B., Samawi, F., Fredericksen, A. K., Roll, D., Oxnard, A., Lê Cook, B., & Schuman-Olivier, Z. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108415 · Cited by 14 · see citing works
Moore, S. K., Okst, K., Smith, L., Fatkin, T., Creedon, T., Fredericksen, A. K., Gawande, R., & Schuman-Olivier, Z. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.780383 · Cited by 12 · see citing works
Rosansky, J. A., Howard, L., Goodman, H., Okst, K., Fatkin, T., Fredericksen, A. K., Sokol, R., Gardiner, P., Parry, G., Cook, B. L., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107417 · Cited by 3 · see citing works
- Authors
- Price, C. J., Merrill, J. O., McCarty, R. L., Pike, K. C., & Tsui, J. I.
- Affiliations
- University of Washington (US)
- Corresponding author
- Price, Cynthia J.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 108
- Pages
- 123-128
- ISSN
- 0740-5472 (ISSN-L)
- PMC
- PMC6874727
- OpenAlex
- W2946162759
- Cited by
- 33
- References
- 44
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 1 · 2019: 4
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Substance Abuse Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Center for Complementary and Integrative Health
- National Institutes of Health (R21AT009932)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- opioid use disorder, interoceptive awareness, buprenorphine, adjunctive psychotherapy, treatment acceptability, emotion regulation, self-care
- MeSH terms
- Adult, Analgesics, Opioid, Awareness, Buprenorphine, Female, Humans, Male, Opioid-Related Disorders, Pilot Projects, Surveys and Questionnaires, Patient Satisfaction, Mind-Body Therapies, Self Report, Mindfulness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
